GLP-1 (semaglutide/tirzepatide) safety surveillance intensifies — FDA reporting concerns, ocular NAION signal, stopping-risk data
Key Questions
What FDA concerns exist for semaglutide like Ozempic?
FDA criticized Novo for underreporting adverse events with semaglutide. Safety surveillance is intensifying, including signals for ocular NAION. Report all side effects promptly.
Is there a link between GLP-1 drugs and vision problems?
Emerging data links semaglutide and tirzepatide to NAION, a type of optic nerve damage. Monitor vision changes closely while on these medications. Consult an eye specialist if issues arise.
What happens if you stop GLP-1 medications abruptly?
Stopping leads to 50-75% dropout rates within a year, raising CV risk by 8% at 6 months and 22% at 2 years in T2D patients. Rapid benefit erosion occurs, so avoid abrupt stops. Taper under medical supervision.
How does alcohol interact with GLP-1 drugs like Ozempic?
Alcohol worsens hypoglycemia, nausea, and dehydration risks, especially in frail patients. Limit intake and monitor closely. Lifestyle changes enhance safety over dose escalation.
What other risks are associated with long-term GLP-1 use?
Muscle loss, frailty, nutrition issues, and mood changes like anhedonia during dose escalation. Telehealth compounded versions add variability. Individualize for elders and combine with lifestyle synergy.
FDA criticized Novo for semaglutide underreporting; NAION links; 50-75% 1-yr dropouts raise CV risk 8% at 6mo/22% at 2y (330k T2D vets), rapid CV benefit erosion on discontinuation, dose escalation accumulation (anhedonia/crashes), lifestyle synergy cuts risks, alcohol worsens hypo/nausea/dehydration in frail; NICE SELECT modest benefits (MI 1% NNT100); added muscle loss/frailty/nutrition risks; telehealth safety gaps incl compounded variability; NHS Wegovy CV rollout signals. Avoid abrupt stops, monitor vision/mood/frailty, individualize elders, report AEs.